Published on 19 Dec 2022 on Zacks via Yahoo Finance

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

Sanofi SNY and partner Regeneron REGN announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has rendered a positive opinion recommending the approval of Dupixent (dupilumab) for treating adults and adolescents with eosinophilic esophagitis, a chronic inflammatory disease.

A final decision from the European Commission is expected in the upcoming months. If approved in Europe, Dupixent will become the first and only targeted medicine indicated for people aged 12 years and older with eosinophilic esophagitis in the country.

Dupixent was approved by the FDA for the treatment of eosinophilic esophagitis in patients aged 12 years and above in May 2022. It is the only medicine currently approved for treating eosinophilic esophagitis in the United States.